ARE Stock Analysis: Alexandria Real Estate | NYSE
REIT - Office | NYSE, USA | Market Cap: 7.163m USD | 12M Return: -41.7% | US0152711091 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 94.8M
Qual. Beats: 0
Rev. Trend: 46.4%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alexandria Real Estate Equities (NYSE: ARE) is an S&P 500 life science REIT founded in 1994 and widely credited with pioneering the life science real estate niche. The company owns, operates, and develops collaborative Megacampus ecosystems in top-tier innovation cluster locations, including Greater Boston, San Diego, the San Francisco Bay Area, Seattle, Maryland, Research Triangle, and New York City. The company is incorporated in Maryland and trades as a mid-cap stock following its 1997 IPO, and is the longest-tenured operator in its niche.
As a specialized REIT, Alexandria leases laboratory and research facilities to tenants in the pharmaceutical, biotechnology, and medical technology sectors. Under U.S. tax rules, REITs must distribute at least 90% of their taxable income to shareholders as dividends, which typically positions REIT shares as income-oriented holdings relative to the broader equity market.
- Biotech venture funding rebound lifts lab occupancy
- Interest rate cuts ease REIT cap rate pressure
- Megacampus development pipeline expands in Boston and San Diego
| Net Income: -904.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.24 > 1.0 |
| NWC/Revenue: -139.6% < 20% (prev -69.07%; Δ -70.55% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.28b > Net Income -904.0m |
| Net Debt (12.7b) to EBITDA (425.6m): 29.83 < 3 |
| Current Ratio: 0.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (188.4m) vs 12m ago 10.72% < -2% |
| Gross Margin: 69.46% > 18% (prev 69.38%; Δ 0.08% > 0.5%) |
| Asset Turnover: 8.19% > 50% (prev 8.03%; Δ 0.16% > 0%) |
| Interest Coverage Ratio: -3.39 > 6 (EBIT TTM -846.5m / Interest Expense TTM 249.5m) |
| DSRI: 0.10 (Receivables 7.66m/283.3m, Revenue 2.96b/3.02b) |
| GMI: 1.00 (GM 69.38% / 69.46%) |
| AQI: 0.12 (AQ_t 0.12 / AQ_t-1 0.95) |
| SGI: 0.98 (Revenue 2.96b / 3.02b) |
| TATA: -0.06 (NI -904.0m - CFO 1.28b) / TA 34.6b) |
| Beneish M = -4.31 (Cap -4..+1) = AAA |
As of October 22, 2026, the stock is trading at USD 42.26 with a total of 2,373,274 shares traded. Over the past week, the price has changed by +1.83%, over one month by -19.58%, over three months by -15.24% and over the past year by -41.66%.
Current recommended Stop Loss: 39.80 (which is 5.8% or 1.4 ATR below the current price).
Alexandria Real Estate has received a consensus analysts rating of 2.88. Therefore, it is recommended to hold ARE.
- StrongBuy: 2
- Buy: 0
- Hold: 10
- Sell: 2
- StrongSell: 2
| Analysts Target Price | 51.9 | 22.9% |
P/E Forward = 16.6945
P/S = 2.5218
P/B = 0.5738
P/EG = 3.2356
Revenue TTM = 2.96b USD
EBIT TTM = -846.5m USD
EBITDA TTM = 425.6m USD
Long Term Debt = 10.8b USD (from longTermDebt, last quarter)
Short Term Debt = 1.99b USD (from shortTermDebt, last quarter)
Debt = 13.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 354.9m
Net Debt = 12.7b USD (calculated: Debt 13.2b - CCE 470.4m)
Enterprise Value = 19.9b USD (7.16b + Debt 13.2b - CCE 470.4m)
Interest Coverage Ratio = -3.39 (Ebit TTM -846.5m / Interest Expense TTM 249.5m)
EV/FCF = 22.67x (Enterprise Value 19.9b / FCF TTM 876.1m)
FCF Yield = 4.41% (FCF TTM 876.1m / Enterprise Value 19.9b)
FCF Margin = 29.63% (FCF TTM 876.1m / Revenue TTM 2.96b)
Net Margin = -30.57% (Net Income TTM -904.0m / Revenue TTM 2.96b)
Gross Margin = 69.46% ((Revenue TTM 2.96b - Cost of Revenue TTM 903.3m) / Revenue TTM)
Gross Margin QoQ = 73.95% (prev 66.60%)
Tobins Q-Ratio = 0.57 (Enterprise Value 19.9b / Total Assets 34.6b)
Interest Expense / Debt = 1.89% (Interest Expense 249.5m / Debt 13.2b)
Taxrate = 16.39% (9.03m / 55.1m)
NOPAT = -707.8m (EBIT -846.5m * (1 - 16.39%)) [loss with tax shield]
Current Ratio = 0.11 (Total Current Assets 510.1m / Total Current Liabilities 4.64b)
Debt / Equity = 0.85 (Debt 13.2b / totalStockholderEquity, last quarter 15.6b)
Debt / EBITDA = 29.83 (Net Debt 12.7b / EBITDA 425.6m)
Debt / FCF = 14.49 (Net Debt 12.7b / FCF TTM 876.1m)
Total Stockholder Equity = 15.8b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.50% (Net Income -904.0m / Total Assets 34.6b)
RoE = -5.70% (Net Income TTM -904.0m / Total Stockholder Equity 15.8b)
RoCE = -3.17% (EBIT -846.5m / Capital Employed (Equity 15.8b + L.T.Debt 10.8b))
RoIC = -2.22% (negative operating profit) (NOPAT -707.8m / Invested Capital 31.8b)
WACC = 3.38% (E(7.16b)/V(20.3b) * Re(6.69%) + D(13.2b)/V(20.3b) * Rd(1.89%) * (1-Tc(0.16)))
Discount Rate = 6.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 62.27 | Cagr: 4.14%
[DCF] Terminal Value 73.10% ; FCFF base≈1.09b ; Y1≈959.0m ; Y5≈774.8m
[DCF] Fair Price = N/A (negative equity: EV 12.4b - Net Debt 12.7b = -260.3m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.03 | # QB: 0
Revenue Correlation: 46.37 | Revenue CAGR: 1.52% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.00 | Chg30d=+100.00% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=1.46 | Chg30d=-0.34% | Revisions=-25% | GrowthEPS=+117.3% | GrowthRev=-13.3%
EPS next Year (2027-12-31): EPS=-0.81 | Chg30d=+7.95% | Revisions=+25% | GrowthEPS=-134.7% | GrowthRev=-3.8%
[Analyst] Revisions Ratio: +17% (up=2, down=1)